盐酸阿罗洛尔对非卧床持续性腹膜透析高血压疗效观察

Effectiveness of arotinolol in treating obstinate hypertension and lipid metabolic disorder in continuous ambulatory peritoneal dialysis patients

目的研究盐酸阿罗洛尔对非卧床持续性腹膜透析（CAPD）高血压患者的降压疗效。方法选择CAPD高血压患者38例，分为治疗组（20例）与对照组（18例）。治疗组给予口服盐酸阿罗洛尔10mg／次，每天1次，共治疗4周。观察治疗前后血压、心率及胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）、载脂蛋白Al（Apo-Al）、载脂蛋白B（Apo-B）的变化。对照组患者维持原治疗方案不变，分别于实验前后检测相应指标。结果4周后，治疗组患者血压、心率明显下降，与治疗前及对照组比较均有显著差异（P〈0．01）；治疗组患者治疗前后TC、TG、HDL、LDL、Apo—Al、Apo—B无显著变化（P〉0．05）。结论盐酸阿罗洛尔对CAPD高血压患者有治疗效果，同时短期内不影响CAPD患者脂质代谢。

Objective To study the effectiveness of arotinolol in treating obstinate nypertension and lipid metabolic disorder in continuous ambulatory peritoneal dialysis（CAPD） patients. Method Thirty-eight CAPD patients with obstinate hypertension were randomly divided into treatment group （n = 20） and control group （n = 18）. The patients in treatment group were treated with daily doses of 10 mg arotinolol for 4 weeks, and the ambulatory blood pressure, heart rate, cholesterol, triglyceride, high-density-lipoprotein, low-density-lipoprotein, apolipoprotein-Al, apolipoprotein-B were monitored before and after the treatment. Result After 4 weeks in treatment group the mean blood pressure and heart rate were decreased obv）ously, btt there was no significant changes in cholesterol, triglyceride, high-density-lipoprotein, low-density-lipoprotein, apolipoprotein-Al, apolipoprotein-B. Conclusion Arotinolol is effective in treating obstinate hypertensio, associated with CAPD and can not aggravate lipid metabolic disorder in a short period.